The DOI matches its Crossref record; 277 of the 277 references it cites were found in a registry or an index.
Kinase-targeted cancer therapies: progress, challenges and future directions
Open accessAbstract
The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein-coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–277 of 277
Tang, F., Nguyen, N. T., & Meydani, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11325 · Cited by 118
The ABC of protein kinase conformations
Möbitz, H. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.03.009 · Cited by 116
Quercetin inhibits a large panel of kinases implicated in cancer cell biology
Kiss (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.890 · Cited by 116
Wu, J.-C., Lai, C., Badmaev, V., Nagabhushanam, K., Ho, C., & Pan, M. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100454 · Cited by 114
Sphingosine Kinase 1 in Cancer
Heffernan-Stroud, L. A., & Obeid, L. M. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-394274-6.00007-8 · Cited by 114
The rise and fall of gatekeeper mutations? The BCR‐ABL1 T315I paradigm
Gibbons, D. L., Pricl, S., Kantarjian, H. M., Cortes, J. E., & Quintás‐Cardama, A. (2011) · Cancer · doi:10.1002/cncr.26225 · Cited by 112
Han, S., Mistry, A., Chang, J. S., Cunningham, D., Griffor, M., Bonnette, P. C., Wang, H., Chrunyk, B. A., Aspnes, G. E., Walker, D. P., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809038200 · Cited by 110
Kaur, P., Shukla, S., & Gupta, S. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn201 · Cited by 110
Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
Blanc, J., Geney, R., & Menet, C. J. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313050008 · Cited by 105
Disrupting the Scaffold to Improve Focal Adhesion Kinase–Targeted Cancer Therapeutics
Cance, W. G., Kurenova, E., Marlowe, T. A., & Golubovskaya, V. (2013) · Science Signaling · doi:10.1126/scisignal.2004021 · Cited by 98
Rajasingh, J., Raikwar, H. P., Muthian, G., Johnson, C., & Bright, J. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.014 · Cited by 95
Li, Y., Liu, J., Liu, X., Xing, K., Wang, Y., Li, F., & Yao, L. (2006) · Applied Biochemistry and Biotechnology · doi:10.1385/abab:135:3:181 · Cited by 95
Hasinoff, B. B. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.032 · Cited by 95
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.011 · Cited by 94
Huang, C., Chan, C., Chou, I., Lien, C., Hung, H., & Lee, M. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.01.010 · Cited by 93
Wolanin, K., Magalska, A., Mosieniak, G., Klinger, R. W., McKenna, S. L., Vejda, S., Sikora, E., & Piwocka, K. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0172 · Cited by 93
Cancer-linked targets modulated by curcumin.
Hasima, N., & Aggarwal, B. B. (2012) · PubMed · Cited by 92
Heymach, J. V., Nilsson, M. B., Blumenschein, G., Papadimitrakopoulou, V. A., & Herbst, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0286 · Cited by 88
Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB.
Mirza, A. M., Kohn, A. D., Roth, R. A., & McMahon, M. (2000) · PubMed · Cited by 87
Yu, P., Laird, A., Du, X., Wu, J., Won, K., Yamaguchi, T., Hsu, P. P., Qian, F., Jaeger, C. T., Zhang, W., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0709 · Cited by 86
Hayashi, T., Seiler, R., Oo, H. Z., Jäger, W., Moskalev, I., Awrey, S. J., Dejima, T., Todenhöfer, T., Li, N., Fazli, L., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.05.087 · Cited by 84
Polo-like kinase 1 as target for cancer therapy
Weiß, L., & Efferth, T. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-38 · Cited by 84
Warburton, C., Dragowska, W. H., Gelmon, K. A., Chia, S., Yan, H., Masin, D., Denyssevych, T., Wallis, A. E., & Bally, M. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0244 · Cited by 83
Chen, L.-X., He, Y.-J., Zhao, S.-Z., Wu, J.-G., Wang, J.-T., Zhu, L.-M., Lin, T.-T., Sun, B., & Li, X.-R. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.13842 · Cited by 82
Drug discovery and the human kinome: Recent trends
Eglen, R. M., & Reisine, T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.007 · Cited by 80
Brizuela, L., Dayon, A., Doumerc, N., Ader, I., Golzio, M., Izard, J., Hara, Y., Malavaud, B. A., & Cuvillier, O. (2010) · The FASEB Journal · doi:10.1096/fj.10-160838 · Cited by 78
Khan, A., Aljarbou, A. N., Aldebasi, Y. H., Faisal, S. M., & Khan, M. A. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2014.09.006 · Cited by 77
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Wissner, A., Fraser, H. L., Ingalls, C. L., Dushin, R. G., Floyd, M. B., Cheung, K., Nittoli, T., Ravi, M., Tan, X., & Loganzo, F. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.055 · Cited by 76
Irreversible Protein Kinase Inhibitors
Garuti, L., Roberti, M., & Bottegoni, G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391705 · Cited by 76
Overexpression of Active Aurora-C Kinase Results in Cell Transformation and Tumour Formation
Khan, J., Ezan, F., Crémet, J.-Y., Fautrel, A., Gilot, D., Lambert, M., Benaud, C. M., Troadec, M., & Prigent, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026512 · Cited by 75
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
Converso, A., Hartingh, T. J., Garbaccio, R. M., Tasber, E. S., Rickert, K. W., Fraley, M. E., Yan, Y., Kreatsoulas, C., Stirdivant, S. M., Drakas, B. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.076 · Cited by 75
Recent Advances of MEK Inhibitors and Their Clinical Progress
Wang, J. Y., Wilcoxen, K., Kenichi, N., & Wu, S. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607781696837 · Cited by 75
Maekawa, T., Ashihara, E., & Kimura, S. H. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0699-1 · Cited by 72
Guertin, K. R., & Grimsby, J. S. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777452551 · Cited by 72
Cyclin-Dependent Kinase Modulators and Cancer Therapy
Gallorini, M., Cataldi, A., & di Giacomo, V. (2012) · BioDrugs · doi:10.1007/bf03261895 · Cited by 71
Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics
Kirkland, L. O., & McInnes, C. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.022 · Cited by 68
Akt is a direct target for myricetin to inhibit cell transformation
Kumamoto, T., Fujii, M., & Hou, D. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0171-9 · Cited by 68
Aurora kinase inhibition downregulates NF-κB and sensitises tumour cells to chemotherapeutic agents
Sun, C., Chan, F., Briassouli, P., & Linardopoulos, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.004 · Cited by 67
Massarweh, S. A., Romond, E. H., Black, E. P., Dressler, E. V. M., Shelton, B. J., Kadamyan, V., Stevens, M., & Elledge, R. M. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2810-9 · Cited by 65
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Fabbro, D., Manley, P. W., Jahnke, W., Liebetanz, J., Szyttenholm, A., Fendrich, G., Strauss, A., Zhang, J., Gray, N. S., Adrián, F., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.009 · Cited by 64
Chadalapaka, G., Jutooru, I., & Safe, S. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs102 · Cited by 60
Lim, K. G., Gray, A. I., Pyne, S., & Pyne, N. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01862.x · Cited by 59
Oncology Drug Discovery: Planning a Turnaround
Toniatti, C., Jones, P. S., Graham, H., Pagliara, B., & Draetta, G. F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0452 · Cited by 59
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes
Angell, R. M., Angell, T. D., Bamborough, P., Bamford, M. J., Chung, C., Cockerill, S. G., Flack, S. S., Jones, K. L., Lainé, D. I., Longstaff, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.028 · Cited by 58
Anagnostopoulou, V., Pediaditakis, I., Alkahtani, S. H., Alarifi, S. A., Schmidt, E.-M., Lang, F. J. W., Gravanis, A., Charalampopoulos, I., & Stournaras, C. (2013) · Endocrinology · doi:10.1210/en.2012-2249 · Cited by 58
Advances of small molecule targeting of kinases
Berndt, N., Karim, R. M., & Schönbrunn, E. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.015 · Cited by 58
Eriksson, A., Österroos, A., Hassan, S., Gullbo, J., Rickardson, L., Jarvius, M., Nygren, P., Fryknäs, M., Höglund, M., & Larsson, R. L. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.31 · Cited by 57
Sandberg, D., Максимилианович, Т. В., Velikyan, I., Olofsson, H., Wennborg, A., Feldwisch, J., Carlsson, J., Lindman, H., & Sørensen, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3650-3 · Cited by 57
Aurora Kinase Inhibition As an Anticancer Strategy
Hilton, J. F., & Shapiro, G. I. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7988 · Cited by 56
Patel, R. Y., & Doerksen, R. J. (2010) · Journal of Proteome Research · doi:10.1021/pr100662s · Cited by 55
Curcumin protects the developing lung against long-term hyperoxic injury
Sakurai, R., Villarreal, P., Husain, S., Liu, J., Sakurai, T., Tou, E., Torday, J. S., & Rehan, V. K. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00082.2013 · Cited by 55
Protein Kinase Inhibition: Different Approaches to Selective Inhibitor Design
Scapin, G. (2006) · Current Drug Targets · doi:10.2174/1389450110607011443 · Cited by 52
Recently targeted kinases and their inhibitors—the path to clinical trials
Knapp, S., & Sundström, M. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.015 · Cited by 50
Masuda, M., Wakasaki, T., Toh, S., Shimizu, M., & Adachi, S. (2011) · Journal of Oncology · doi:10.1155/2011/540148 · Cited by 50
The Importance of a Gatekeeper Residue on the Aggregation of Transthyretin
Sant’Anna, R., Braga, C. A. C. A., Varejão, N., Pimenta, K. M., Graña‐Montes, R., Alves, A. A., Cortines, J. R., Cordeiro, Y., Ventura, S., & Foguel, D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.563981 · Cited by 48
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
Wang, A., Yan, X.-E., Wu, H. Y., Wang, W., Chen, H., Cheng, C., Zhao, Z., Zhao, P., Li, X., Wang, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11951 · Cited by 47
High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer
Sokołowska-Wędzina, A., Chodaczek, G., Chudzian, J., Borek, A., Zakrzewska, M., & Otlewski, J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0136 · Cited by 46
Xia, Y., Lian, S., Khoi, P. N., Yoon, H. J., Han, J., Chay, K.-O., Kim, K. K., & JUNG, Y. D. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2847 · Cited by 44
Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
Scholtens, A., Foppen, M. H. G., Blank, C. U., van Thienen, J. V., van Tinteren, H., & Haanen, J. B. A. G. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.009 · Cited by 42
Curcumin Blocks RON Tyrosine Kinase–Mediated Invasion of Breast Carcinoma Cells
Narasimhan, M., & Ammanamanchi, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6883 · Cited by 41
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 40
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 39
Sharma, A. K., Madhunapantula, S. V., Gowda, R., Berg, A. S., Neves, R. I., & Robertson, G. P. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.019 · Cited by 38
Jeong, K. J., Cho, K. H., Panupinthu, N., Kim, H., Kang, J., Park, C. G., Mills, G. B., & Lee, H. Y. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.001 · Cited by 38
The evolving field of kinase inhibitors in thyroid cancer
Marotta, V., Sciammarella, C., Vitale, M., Colao, A., & Faggiano, A. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.007 · Cited by 36
Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers
Mikhail, S., Albanese, C., & Pishvaian, M. J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.01.008 · Cited by 36
Role of the JAK‐STAT Signalling Pathway in Cancer
Dutta, P., & Li, W. X. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025214 · Cited by 29
Takeda, M., & Nakagawa, K. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1099 · Cited by 29
A Protein Kinase Inhibitor, Fasudil (AT‐877): A Novel Approach to Signal Transduction Therapy
Asano, T., Ikegaki, I., Satoh, S., et al. (1998) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.1998.tb00346.x · Cited by 24
EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells
Chen, S., Luan, J. Y., Zhang, H.-S., Ruan, C., Xu, X., Li, Q., & Wang, N. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1347-4 · Cited by 17
Targeted therapy with kinase inhibitors in aggressive endocrine tumors
Marotta, V., Franzese, M. D., Prete, M. D., Chiofalo, M. G., Ramundo, V., Esposito, R., Marciello, F., Pezzullo, L., Carratù, A., Vitale, M., et al. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.796931 · Cited by 16
Abdel-Rahman, O. M., & Fouad, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3064-4 · Cited by 15
Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
Normanno, N., Campiglio, M., Perrone, F., Luca, A. D., & Ménard, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi325 · Cited by 11
Targeting CK2 for Cancer Therapy Using a Nanomedicine Approach
Ahmed, K., Unger, G. M., Kren, B. T., & Trembley, J. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-14544-0_17 · Cited by 9
Bedard, P. L., Grilley‐Olson, J. E., Cornfeld, M. J., Cartee, L., Warwick, S., Razak, A. A., Stayner, L.-A., Wu, Y., Greenwood, R., Viana-Gilmartin, V., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct205 · Cited by 3
Massarweh, S. A., Romond, E. H., Black, E. P., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3263-0 · Cited by 2
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Targeting RNA structures with small molecules
Childs-Disney, J. L., Yang, X., Gibaut, Q. M. R., Tong, Y., Batey, R. T., & Disney, M. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00521-4 · Cited by 587
Metadata
- Authors
- Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V.
- Venue
- Molecular Cancer
- Published
- 2018-02-19
- Volume
- 17
- Issue
- 1
- Pages
- 48-48
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2794930605
- Cited by
- 1,245
- References
- 277
- FWCI
- 71.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.